Market Closed -
Nasdaq
04:00:00 2025-02-12 pm EST
5-day change
1st Jan Change
117.18 USD
+0.28%
-23.12%
-14.15%
Neurocrine Biosciences' Crenessity Approved by FDA for Classic Congenital Adrenal Hyperplasia
December 16, 2024 at 07:31 am EST
Voyager Therapeutics Shares Fall After Dropping Plan for VY9323 IND Filing in Mid-2025
Feb. 11
MT
Deutsche Bank Initiates Coverage on Neurocrine Biosciences With Hold Rating, $138 Price Target
Feb. 11
MT
Voyager Therapeutics, Inc. Provides Update on Sod1 Als Gene Therapy Program
Feb. 11
CI
UBS Adjusts Neurocrine Biosciences Price Target to $154 From $176, Maintains Buy Rating
Feb. 10
MT
Tranche Update on Neurocrine Biosciences, Inc.'s Equity Buyback Plan announced on October 30, 2024.
Feb. 07
CI
RBC Capital Adjusts Price Target on Neurocrine Biosciences to $148 From $154, Keeps Sector Perform Rating
Feb. 07
MT
Wedbush Adjusts Price Target on Neurocrine Biosciences to $147 From $157, Keeps Outperform Rating
Feb. 07
MT
Sector Update: Health Care Stocks Lower Pre-Bell Friday
Feb. 07
MT
Sector Update: Health Care
Feb. 07
MT
Neurocrine Biosciences, Inc.'s Equity Buyback announced on October 30, 2024, has closed with 2,295,510 shares, representing 2.27% for $300 million.
Feb. 06
CI
Neurocrine Biosciences, Inc., Q4 2024 Earnings Call, Feb 06, 2025
Feb. 06
Neurocrine Biosciences Q4 Non-GAAP Earnings, Revenue Rise
Feb. 06
MT
Earnings Flash (NBIX) Neurocrine Biosciences, Reports Q4 Adjusted EPS $1.69
Feb. 06
MT
Earnings Flash (NBIX) Neurocrine Biosciences, Posts Q4 Revenue $627.7M, vs. FactSet Est of $629.5M
Feb. 06
MT
Neurocrine Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024
Feb. 06
CI
Neurocrine Biosciences, Inc. Provides Sales Guidance for the Full Year 2025
Feb. 06
CI
Neurocrine Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024
Feb. 06
CI
Neurocrine Biosciences Insider Sold Shares Worth $413,967, According to a Recent SEC Filing
Feb. 04
MT
Neurocrine Biosciences Insider Sold Shares Worth $21,836,503, According to a Recent SEC Filing
Jan. 30
MT
Neurocrine Biosciences Begins Phase 3 Study of Osavampator in Major Depressive Disorder
Jan. 28
MT
Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults
Jan. 28
CI
Stocks to Watch : Graco, Brown & Brown, Neurocrine Biosciences
Jan. 27
DJ
Neurocrine Amends Agreement With Takeda for Major Depressive Disorder Treatment
Jan. 27
DJ
Neurocrine Amends Collaboration with Takeda on Osavampator
Jan. 27
MT
Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator
Jan. 27
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
NBIX: Dynamic Chart
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntingtonâs disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
More about the company
Last Close Price
116.85 USD
Average target price
166.45 USD
Spread / Average Target
+42.45%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1